within Pharmacolibrary.Drugs.L_AntineoplasticAndImmunomodulatingAgents.L04A_Immunosuppressants.L04AC23_Olokizumab;
model Olokizumab 
   extends Pharmacolibrary.Drugs.ATC.L.L04AC23;

  annotation(Documentation(
    info ="<html><body><p>Olokizumab is a humanized monoclonal antibody targeting interleukin-6 (IL-6), used for the treatment of adults with moderate to severe active rheumatoid arthritis who have had an inadequate response or intolerance to disease-modifying antirheumatic drugs (DMARDs). It was approved in Russia in 2020 for rheumatoid arthritis and is under clinical development elsewhere.</p><h4>Pharmacokinetics</h4><p>Pharmacokinetic estimates for olokizumab in adult patients with rheumatoid arthritis based on typical monoclonal antibody PK behavior and limited published clinical data.</p><h4>References</h4><ol><li><p>Kretsos, K, Golor, G, Jullion, A, Hickling, M, McCabe, S, Shaw, S, Jose, J, &amp; Oliver, R (2014). Safety and pharmacokinetics of olokizumab, an anti-IL-6 monoclonal antibody, administered to healthy male volunteers: A randomized phase I study. <i>Clinical pharmacology in drug development</i> 3(5) 388–395. DOI:<a href=&quot;https://doi.org/10.1002/cpdd.121&quot;>10.1002/cpdd.121</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/27129012/&quot;>https://pubmed.ncbi.nlm.nih.gov/27129012</a></p></li><li><p>Agachi, S, Beloukhova, M, Mould, D, Lemak, M, Grishin, S, &amp; Samsonov, M (2024). Inflammation-mediated drug interactions of olokizumab and cytochrome P450 activities in patients with rheumatoid arthritis. <i>British journal of clinical pharmacology</i> 90(11) 2811–2822. DOI:<a href=&quot;https://doi.org/10.1111/bcp.16175&quot;>10.1111/bcp.16175</a>  PUBMED:<a href=&quot;https://pubmed.ncbi.nlm.nih.gov/38984761/&quot;>https://pubmed.ncbi.nlm.nih.gov/38984761</a></p></li></ol></body></html>",
    revisions = "<html><body><ul><li>06/2025 model generated by LLM gpt-4.1, references by scholarly and scripts created by Tomas Kulhanek</li></ul></body></html>",
    experiment(StartTime = 0, StopTime = 86400, Tolerance = 1e-09, Interval = 1)
  ));  
end Olokizumab;
